News

News

Press releases

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

view all Tweets

Twitter

@KynTherapeutics
Our VP of Business Development, @maude_tessier, will be at @EBDgroup's BioPharm America conference during… http://KOCkftLQ9F

@KynTherapeutics
#ICYMI Our CEO, @markgmanfredi, discussed our approach of reigniting the immune system to address different forms o… http://wzdnYdFzDv

@KynTherapeutics
We're proud to display some new artwork this month from local artists in #Boston and #Cambridge! There's a well-stu… http://DV0uTSns3r

@KynTherapeutics
Excellent deep dive from @cenmag's @lisamjarvis on explosion of interest in #immunooncology combinations:… http://VMZ1CiQgqx

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
1030 Massachusetts Avenue
Suite 400
Cambridge, MA 02138

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn